Business Description
Evotec SE
ISIN : DE0005664809
Share Class Description:
EVOTF: Ordinary SharesTotal Employee Number:
4,553Description
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.2 | |||||
Equity-to-Asset | 0.43 | |||||
Debt-to-Equity | 0.55 | |||||
Debt-to-EBITDA | -2.36 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 0.12 | |||||
Beneish M-Score | -3.42 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.4 | |||||
3-Year EPS without NRI Growth Rate | -45.9 | |||||
3-Year Book Growth Rate | -11.9 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 3.93 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 99.94 | |||||
9-Day RSI | 97.2 | |||||
14-Day RSI | 87.55 | |||||
3-1 Month Momentum % | 27.67 | |||||
6-1 Month Momentum % | -16.48 | |||||
12-1 Month Momentum % | -19.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.68 | |||||
Quick Ratio | 1.6 | |||||
Cash Ratio | 1.1 | |||||
Days Inventory | 17.88 | |||||
Days Sales Outstanding | 57.85 | |||||
Days Payable | 31.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 11.74 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 11.47 | |||||
Operating Margin % | -11.06 | |||||
Net Margin % | -26.02 | |||||
EBITDA Margin % | -22.08 | |||||
FCF Margin % | -7.14 | |||||
OCF Margin % | 2.46 | |||||
ROE % | -23.81 | |||||
ROA % | -10.92 | |||||
ROIC % | -5.86 | |||||
3-Year ROIIC % | 37.62 | |||||
ROC (Joel Greenblatt) % | -24 | |||||
ROCE % | -11.79 | |||||
Years of Profitability over Past 10-Year | 6 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 278.75 | |||||
PS Ratio | 1.17 | |||||
PB Ratio | 1.25 | |||||
Price-to-Tangible-Book | 2.21 | |||||
Price-to-Operating-Cash-Flow | 46.28 | |||||
EV-to-EBIT | -4.83 | |||||
EV-to-Forward-EBIT | -10.6 | |||||
EV-to-EBITDA | -4.83 | |||||
EV-to-Forward-EBITDA | 19.91 | |||||
EV-to-Revenue | 1.07 | |||||
EV-to-Forward-Revenue | 1.12 | |||||
EV-to-FCF | -15.04 | |||||
Price-to-GF-Value | 0.64 | |||||
Price-to-Median-PS-Value | 0.17 | |||||
Earnings Yield (Greenblatt) % | -20.7 | |||||
FCF Yield % | -6.07 | |||||
Forward Rate of Return (Yacktman) % | 25.9 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:EVOTF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Evotec SE Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 867.523 | ||
| EPS (TTM) ($) | -1.252 | ||
| Beta | 1.1256 | ||
| 3-Year Sharpe Ratio | -0.49 | ||
| 3-Year Sortino Ratio | -0.64 | ||
| Volatility % | 51.19 | ||
| 14-Day RSI | 87.55 | ||
| 14-Day ATR ($) | 0.009078 | ||
| 20-Day SMA ($) | 6.69 | ||
| 12-1 Month Momentum % | -19.11 | ||
| 52-Week Range ($) | 4.725 - 8.58 | ||
| Shares Outstanding (Mil) | 177.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Evotec SE Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Evotec SE Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 | In 129 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 129 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-13 | In 45 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 45 days | ||
| General meeting for 2026 | 2026-06-11 09:00 | 6.69 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 08:00 | 5.24 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 5.24 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-04-08 08:00 | 5.24 (+0.00%) | ||
| Annual report for 2025 | 2026-04-08 | 5.24 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-08 | 5.24 (+0.00%) |
Show
Entries
Evotec SE Frequently Asked Questions
What is Evotec SE(EVOTF)'s stock price today?
The current price of EVOTF is $6.69. The 52 week high of EVOTF is $8.58 and 52 week low is $4.72.
When is next earnings date of Evotec SE(EVOTF)?
The next earnings date of Evotec SE(EVOTF) is 2026-08-13.
Does Evotec SE(EVOTF) pay dividends? If so, how much?
Evotec SE(EVOTF) does not pay dividend.
Guru Commentaries on OTCPK:EVOTF
No articles.
Press Release
Articles on Evotec SE
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers